Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at Wedbush issued their FY2029 earnings estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.08) per share for the year. Wedbush has a "Neutral" rating and a $4.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36.
Other equities research analysts have also issued reports about the stock. UBS Group reduced their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. HC Wainwright cut their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, January 29th. Finally, Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals has an average rating of "Hold" and a consensus target price of $8.24.
View Our Latest Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Price Performance
Shares of ZNTL stock traded down $0.06 during trading hours on Friday, reaching $1.63. 1,745,317 shares of the stock were exchanged, compared to its average volume of 2,825,820. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $18.07. The business's fifty day moving average is $2.90 and its two-hundred day moving average is $3.24. The firm has a market capitalization of $115.81 million, a P/E ratio of -0.65 and a beta of 1.86.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
A number of hedge funds have recently modified their holdings of the business. Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Paloma Partners Management Co purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Aigen Investment Management LP acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $41,000. Ieq Capital LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter valued at $46,000. Finally, Capstone Investment Advisors LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter worth $48,000.
Zentalis Pharmaceuticals Company Profile
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Stories
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
